Trials / Completed
CompletedNCT05895266
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
A Phase 1 Open-Label Drug-Drug Interaction Study Between ABBV-903 and Midazolam
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to assess the drug-drug interaction and pharmacokinetics of ABBV-903 and Midazolam in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-903 | Oral Tablet |
| DRUG | Midazolam | Oral Liquid |
Timeline
- Start date
- 2023-06-23
- Primary completion
- 2023-11-02
- Completion
- 2023-11-02
- First posted
- 2023-06-08
- Last updated
- 2023-11-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05895266. Inclusion in this directory is not an endorsement.